Fig. 1. Circulating Hpx levels in two patient cohorts.

(A and B) Change in plasma Hpx as measured between 6 weeks and 3 months following initiation of anthracyclines was associated with change in GLS (absolute value) at 3 months in patients with breast cancer enrolled in the discovery and validation cohorts, respectively. (C) Absolute value of plasma Hpx at baseline (before anthracyclines) and at 6 weeks following the initiation of anthracyclines in the validation cohort, as measured by ELISA. (D) Baseline plasma Hpx concentration was associated with change in GLS at 3 months. All patients were treated with dose-dense doxorubicin and cyclophosphamide (ddAC). Patients denoted in red developed symptoms of heart failure. Pearson’s correlation coefficient was used to compare percent change in ∆Hpx or baseline Hpx to percent change in ∆GLS. ns indicates that there was no significant difference between the groups.